化学发光法检测卵巢癌血清学人附睾蛋白46例临床分析  

Clinical analysis of Serum HE4 by chemiluminescence method in 46 patients with ovarian cancer

作　　者：刘刚[1] 葛鑫[2] 

机构地区：[1]安徽省蚌埠市第三人民医院检验科,233000 [2]蚌埠医学院第一附属医院检验科,安徽蚌埠233004

出　　处：《蚌埠医学院学报》2011年第11期1251-1252,共2页Journal of Bengbu Medical College

摘　　要：目的:探讨人附睾蛋白4(human epididymis gene protein 4,HE4)对临床不同分期卵巢癌的诊断价值及是否优于癌抗原125(cancer antigen 125,CA125)肿瘤标志物。方法:采用全自动化学发光法分别检测46例卵巢癌组(其中早期9例、中期31例、晚期6例)、50例盆腔良性瘤组、50名健康女性对照组的HE4含量。结果:卵巢癌组HE4含量均明显高于盆腔良性肿瘤组和健康组(P<0.01);9例早期卵巢癌中的HE4阳性率达78%,而CA125阳性率55%,差异有统计学意义(P<0.05)。结论:HE4是诊断卵巢癌的一项特异性肿瘤标志物,且优于CA125,特别对早期卵巢癌的诊断具有重要意义。Objective：To explore the value of human epididymis protein 4（HE4） in diagnosis of ovarian cancer in different clinical stages,and determine whether HE4 is better than cancer antigen 125（CA125）,another tumor marker of ovarian cancer.Methods：The serum HE4 levels in 46 patients with ovarian cancer（among them,the numbers of early,intermediate and terminal cancer were 9,31 and 6,respectively）,50 patients with benign ovarian tumour and 50 healthy women were measured by automatic chemiluminescence method.Results：The level of serum HE4 was significantly higher in ovarian cancer patients than those in other two groups（P0.01）.In 9 early ovarian cancer patients,the positive rate of HE4 was 78%,which was significantly higher than CA125,the positive rate was 55%.Conclusions：HE4 is a specific marker and it is better than CA125 in diagnosis of ovarian cancer,especially it is important for diagnosis of early ovarian cancer.

关 键 词：卵巢肿瘤 化学发光法 人附睾蛋白4 癌抗原125 

分 类 号：R737.31[医药卫生—肿瘤]